| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454397 | Lung Cancer | 2017 | 23 Pages |
Abstract
Outcomes in this study demonstrate that average treatment costs for metastatic NSCLC in the Netherlands Cancer Institute amount to â¬17,463. Compared to a prior study the average cost for metastatic NSCLC over time in the Netherlands has decreased. A shift of main cost drivers seems to have occurred from inpatient stay, to oncolytic drugs as main contributor. The shift towards treatment cost might become more visible with the introduction of immunotherapy. These results mark the importance of up-to-date cost of illness studies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
W.R. Keusters, V.A. de Weger, A. Hövels, J.H.M. Schellens, G.W.J. Frederix,